Merit Medical Removes Dialysis Catheter Introducer in FDA Class I Recall
Merit Medical announced a Class I FDA recall of its 16F Dual‑Valved Splittable Sheath Introducer, a component used in several dialysis catheter kits. The sheath may fail to split during catheter placement, potentially causing hemorrhage, embolization, thrombosis, or loss of future vascular access. Merit has instructed customers to stop using the introducer, label affected kits and destroy the component, while allowing other kit elements to remain in service. As of Feb. 23, two serious injuries have been reported, but no deaths are linked to the defect.
Why Attend the Toronto Life Sciences and Biotech Summit 2026
The Toronto Life Sciences and Biotech Summit on May 7, 2026 will convene real‑estate developers, biotech executives and ecosystem partners to address funding constraints, talent dynamics, and evolving lab‑space demand in the Greater Toronto Area. Speakers will explore how slower...
Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell — Episode 251
In episode 251 of the Xtalks Life Science Podcast, Kevin Caldwell, CEO and co‑founder of Ossium Health, discusses the company’s pioneering off‑the‑shelf bone‑marrow therapy derived from deceased organ donors. The treatment aims to solve long‑standing clinical and logistical hurdles in...
Top 20 Most Innovative Healthcare Companies in 2026, Per Fast Company
Fast Company’s 2026 list spotlights the 20 most innovative healthcare firms, ranging from biotech pioneers like Children’s Hospital of Philadelphia’s CRISPR therapy to digital‑health platforms such as Lantern and Maven Clinic. The rankings arrive amid a surge in drug approvals—46...
Novartis Slashes 114 More Jobs at New Jersey HQ
Novartis announced a second wave of US layoffs, eliminating 114 positions at its East Hanover, New Jersey headquarters. The cuts are part of a multi‑year restructuring that follows the spin‑off of its generics arm Sandoz and earlier reductions in medical...
Spinal Elements Wins FDA Clearance for Ventana A ALIF System, Expands 3D-Printed Spine Portfolio
Spinal Elements has secured FDA 510(k) clearance for its Ventana A anterior lumbar interbody fusion (ALIF) system, the latest addition to its 3D‑printed titanium spine portfolio. The company reports that the first U.S. cases have already been completed, demonstrating early...
World Hemophilia Day 2026: New Treatment Era and Improving Diagnosis
World Hemophilia Day on April 17, 2026 spotlighted the urgent need to improve diagnosis of hemophilia and related bleeding disorders, with the World Federation of Hemophilia (WFH) estimating that more than three‑quarters of patients remain undiagnosed. The theme underscored a...
Zeto New Wave EEG System Wins FDA Clearance For At-Home Brain Monitoring
Zeto announced FDA 510(k) clearance for its New Wave EEG system, the company’s third FDA‑approved neuro‑diagnostic platform. The device is a 21‑electrode, gel‑free headset designed for short‑term, up‑to‑2.5‑hour recordings in outpatient clinics and patients’ homes. Integrated with Zeto’s cloud and...
FDA Clears Low-Dose MRI Contrast Agent Vueway for Newborns and Infants
The U.S. Food and Drug Administration has granted an expanded indication for Bracco's Vueway (gadopiclenol) injection, allowing its use in neonates and infants for contrast‑enhanced MRI. The macrocyclic agent delivers high‑quality images at half the standard gadolinium dose (0.05 mmol/kg), addressing...
Baebies’ Finder Platform Secures Dual FDA Clearance and CLIA Waiver
Baebies announced that its Finder platform has received FDA 510(k) clearance for a Flu A&B/SARS‑CoV‑2 test and a CLIA waiver, making it the first molecular point‑of‑care system with multifunctional capabilities. The cartridge‑based device delivers PCR‑quality results in 15‑20 minutes, enabling...
Parkinson’s Awareness Month and World Parkinson’s Day 2026: Advocacy and Therapeutic Progress
April marks Parkinson’s Awareness Month, culminating in World Parkinson’s Day on April 11, which unites patients, clinicians and advocates worldwide. The disease now affects roughly 11.8 million people and could rise to 25 million by 2050, making early recognition critical. Recent therapeutic advances...
Lynavoy (Linerixibat) Wins FDA Approval for Rare Liver Disease After Alfasigma-GSK Licensing Deal
Alfasigma secured FDA approval for Lynavoy (linerixibat), the first U.S. therapy specifically indicated for cholestatic pruritus in primary biliary cholangitis (PBC). The approval follows a March licensing agreement with GSK that could be worth up to $690 million, including a $300 million...
Scalable Biologics Production Trends: Featuring Omar Wahab of Lonza — Breakthrough, Episode 250
In episode 250 of the Xtalks Life Science Podcast, Lonza’s Vice President of Bioprocessing Omar Wahab explains why cell‑culture media is a strategic lever for scalable biologics manufacturing. He argues that early formulation choices influence downstream productivity, product quality, and...
Yuviwel Gets FDA Greenlight as First Once‑Weekly Treatment for Dwarfism in Children
Ascendis Pharma’s Yuviwel (navepegritide) received FDA approval as the first once‑weekly therapy for achondroplasia in children aged two and older. The drug, a TransCon CNP formulation, showed a 1.5 cm greater annual height gain versus placebo in a 52‑week trial and...
CSL Plans $1.5B Expansion of Illinois Plasma Therapy Manufacturing Facility
CSL announced a $1.5 billion expansion of its plasma‑therapy manufacturing plant in Kankakee, Illinois, aimed at boosting output of immunoglobulins, albumin and specialty proteins. The project will add at least 300 jobs to the existing 1,200‑person workforce and is expected to...
First In-Room MRI-Guided Breast Biopsy System Gets FDA Clearance
Mammotome received FDA clearance for the Prima MR system, the first in‑room MRI‑guided vacuum‑assisted breast biopsy platform, alongside its HydroMARK Plus MR biopsy site markers. The system lets clinicians perform biopsies directly inside the MRI suite, eliminating patient transfers and streamlining...
Tozorakimab Scores Double Win in Phase III COPD Trials
AstraZeneca announced that its IL‑33 monoclonal antibody tozorakimab achieved its primary endpoints in two Phase III COPD trials, Oberon and Titania. The drug significantly reduced the annual rate of moderate‑to‑severe exacerbations versus placebo across former and current smokers. AstraZeneca positions tozorakimab...
Pharma and Biotech Layoffs 2026 Watch
Pharma and biotech companies continued extensive workforce reductions in early 2026, with Takeda alone eliminating 634 U.S. positions as part of a $1.2 billion annual savings plan, while Amgen, GSK, and Merck KGaA also announced cuts ranging from dozens to several...
Which Pharma Jobs Will Be Most In Demand Over the Next 5 Years?
The pharmaceutical sector is reshaping its workforce as AI, precision medicine, tighter regulations, and global manufacturing scale become central to drug development. Companies are seeking talent that can harness data‑driven discovery, navigate complex clinical trials, and ensure compliance across jurisdictions....
Closing the Gaps in Stroke Care: Access, Innovation and Global Equity
Linnea Burman, President of Medtronic Neurovascular, highlighted that nearly 12 million people suffer a stroke each year and one in four die within a year, underscoring persistent global gaps in prevention, access, and long‑term care. She emphasized that rapid treatment is...
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
IBS Awareness Month 2026: The Hidden Realities of IBS and the IBS Treatment Market
April 2026 marks IBS Awareness Month, spotlighting a condition that affects roughly 10‑15% of the global population and often goes undiagnosed. The campaign emphasizes education, stigma reduction, and earlier detection to improve quality of life. Meanwhile, the global IBS treatment...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Is AI Ready to Transform COA Development?
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
MiniMed Unveils MiniMed Flex, Its Smallest Insulin Pump Yet
MiniMed secured FDA clearance for the MiniMed Flex, its smallest insulin pump yet, featuring a fully smartphone‑controlled, screenless design. The pocket‑sized device is roughly half the size of the 780G and holds a 300‑unit insulin reservoir while integrating continuous glucose...
Autoimmune Immunotherapy Is Shifting Upstream: AnaptysBio on Targeting Pathogenic Immune Cells
Autoimmune drug development is moving upstream, targeting pathogenic immune cells rather than single cytokines. AnaptysBio’s Chief Medical Officer, Paul Lizzul, highlighted the company’s cell‑selective immunomodulation strategy, including CD122 antagonism that modulates both CD4 helper and CD8 cytotoxic T cells. Early‑phase...
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine — Episode 248
The Xtalks Life Science Podcast featured Dr. Steve Levine, Chief Patient Officer at Compass Pathways, discussing the company’s push to develop psilocybin‑based therapies for treatment‑resistant depression (TRD). Levine, a board‑certified psychiatrist and founder of Actify Neurotherapies, highlighted the clinical promise...
World Health Day 2026: Stand with Science and Global Health Equity
World Health Day 2026, observed on April 7, adopts the theme “Together for Health, Stand for Science,” urging global unity around science‑driven health solutions. The WHO highlights One Health—linking human, animal and environmental health—and convenes two flagship events: the One Health...
Syneos Health Expands China Operations with Bestudy CRO Acquisition
Syneos Health completed the acquisition of Shanghai‑based Bestudy Medical Technology on March 20, 2026, adding a fast‑growing Chinese CRO to its global network. Financial terms were not disclosed, and Bestudy will continue operating independently under its own brand. The deal...
New Zepbound Commercial “Watch This” Highlights Long-Term Impact
Eli Lilly launched a Super Bowl commercial for its tirzepatide‑based weight‑loss drug Zepbound, emphasizing real‑world confidence and long‑term health management. The ad cites clinical data showing an average 48‑lb (21%) weight loss and a head‑to‑head SURMOUNT‑5 trial where Zepbound achieved a...
BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis
Bristol Myers Squibb received FDA approval expanding Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first oral selective TYK2 inhibitor for this indication. The label extension is backed by the POETYK PsA-1 and PsA-2 trials, where...
Top 5 Fastest Growing Pharma & Biotech Companies in Europe in 2026
A Financial Times analysis of Statista data identifies Europe’s five fastest‑growing pharma and biotech firms between 2021 and 2024. Italy’s Itaste Medical surged to €18.4 billion in sales, a 2,035% absolute growth, while the UK‑based Grow Group expanded cannabis‑based medicines to...
Top 3 Medtech Companies to Work for in Asia in 2026, Per Financial Times
Asia’s medtech sector is gaining momentum as Singapore became the first nation to achieve the WHO’s highest maturity level for medical‑device regulation, signaling stronger oversight across the product lifecycle. The Financial Times’ 2026 ranking spotlights three leading employers—Baxter International, Medtronic,...
First Surrogate Endpoint in Osteoporosis Clinical Trials with FNIH’s Dr. Tania Kamphaus — Episode 247
On December 2025 the FDA officially qualified dual‑energy X‑ray absorptiometry (DXA) bone density scans as the first surrogate endpoint for fracture outcomes in osteoporosis trials involving post‑menopausal women. The qualification, achieved through a request from the Foundation for the National...
Overcoming Drug Development Obstacles for Some of the Most Challenging Ischemic Conditions
DiaMedica Therapeutics is advancing a recombinant tissue kallikrein (KLK1) to treat ischemic stroke and preeclampsia, leveraging the kallikrein‑kinin pathway to restore microvascular flow. Early trials show maternal blood‑pressure reductions, improved uterine‑artery Doppler indices, and no detectable drug in fetal circulation,...
Top 30 Largest Publicly Traded Healthcare Companies in 2026 by Employee Number
The article ranks the 30 biggest publicly traded healthcare firms by employee headcount, highlighting UnitedHealth’s 400,000 staff and $447.6 billion revenue as the top entry. It notes a 56% jump in global healthcare deal volume to $403 billion in 2025, despite fewer...
Eikon Therapeutics IPO Brings in $381M for Oncology Pipeline
Eikon Therapeutics priced an upsized IPO of 21.2 million shares at $18, raising roughly $381 million and valuing the company at about $860 million. The California‑based biotech focuses on immune‑signaling, DNA‑repair and androgen‑receptor pathways, with its lead candidate EIK1001 – a TLR7/8 dual...
Designing Clinical Trials to Address Asthma and COPD Flare-Ups
Acute asthma and COPD exacerbations remain a costly, life‑threatening gap despite advances in chronic therapies. Connect Biopharma, led by Barry Quart, is the first biotech targeting these flare‑ups with a biologic that blocks IL‑4Rα, aiming to curb upstream inflammation. The...
What Determines Success in Complex MASH Clinical Research Today?
Recent FDA approvals of resmetirom and semaglutide have shifted MASH care from a treatment‑void to a therapeutic reality, prompting sponsors to redesign trial endpoints and enrollment strategies. Non‑invasive diagnostic tools are emerging as potential primary endpoints, reducing reliance on liver...
How Dompé Is Innovating in Neuro-Ophthalmology with the FDA’s CNPV Program
Dompe, a privately owned biopharma, is advancing an intranasal nerve growth factor (NGF) therapy to treat non‑arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss affecting roughly 6,000 U.S. patients annually. The approach leverages NGF’s neuroprotective...
MedTech M&A in 2026: Tracking Deal Activity
Medtech M&A rebounded in 2025 and accelerated in 2026, with firms pursuing targeted acquisitions and divestitures across cardiovascular, diagnostics, and manufacturing. Notable deals include Boston Scientific’s $14.5 billion purchase of Penumbra, Danaher’s $9.9 billion acquisition of Masimo, and Blackstone/TPG’s $18.3 billion takeover of...
National Kidney Month 2026: Breakthrough Kidney Disease Therapies
National Kidney Month 2026 highlights a surge of disease‑modifying kidney therapies as chronic kidney disease affects roughly 35.5 million Americans and 10 % of the global population. Recent Phase III data cement SGLT2 inhibitors and Bayer’s finerenone as standards for slowing CKD progression...
Closing the 9-Year Gap: A New Biomarker Targets the Diagnostic Delay in Axial Spondyloarthritis
Axial spondyloarthritis affects about 1.4% of adults but patients wait an average of nine years for diagnosis in North America, far longer than rheumatoid arthritis. Augurex has introduced SPINEstat, an anti‑14‑3‑η multiplex blood test that can distinguish inflammatory back pain...
Rethinking Endocrine Therapy in ER-Positive Breast Cancer
Dr. Steven Quay, CEO of Atossa Therapeutics, highlighted a new focus on tolerability and prevention in estrogen‑receptor‑positive breast cancer, where five‑year survival now exceeds 90%. Atossa is developing a next‑generation SERM that aims to reduce side‑effects while maintaining efficacy and...
Veradermics $294.8M IPO to Fund Phase III Hair Loss Trials
Veradermics closed a $294.8 million IPO, pricing 17 dollars per share and debuting on the NYSE under the ticker MANE. The capital will fund its late‑stage clinical program for VDPHL01, an extended‑release oral minoxidil aimed at androgenetic alopecia. The company has completed...
From Insights to Impact: Rare Disease Therapies with UCB’s Dr. Kim Moran — Episode 246
UCB’s Senior Vice President Dr. Kim Moran discusses the company’s rare disease pipeline, including therapies for mitochondrial TK2 deficiency, on Xtalks Life Science Podcast episode 246. Moran, who pioneered UCB’s Insights‑to‑Impact function, explains how patient‑derived data informs strategy, digital transformation,...
What Matters More in DNA-Encoded Libraries: Size, Quality or Chemical Diversity?
DNA‑encoded libraries (DELs) enable billions of compounds to be screened, but X‑Chem argues that size alone does not predict success. By limiting synthesis to two‑three cycles, the company creates lead‑like molecules (350‑450 Da) with high three‑dimensional diversity, and its analysis of...
Agomab IPO Raises $200M to Fund Fibrosis Therapies
Agomab Therapeutics NV closed its Nasdaq IPO, raising roughly $200 million by selling 12.5 million American Depositary Shares at $16 each. The capital will fuel its fibrosis‑focused pipeline, beginning with ontunisertib, an oral TGFβ‑ALK5 inhibitor for fibrostenosing Crohn’s disease that achieved its...
Accrufer Becomes First FDA-Approved Prescription Iron Therapy for Children 10+
Shield Therapeutics announced that the FDA has approved Accrufer, its ferric maltol oral iron formulation, for children ages 10 and older, making it the first prescription oral iron therapy for this age group. The approval expands the drug’s label beyond...
Norgine Announces £23 Million Investment to Expand Medicines Manufacturing in Wales
Norgine announced a £23 million injection to expand its Hengoed, Wales, manufacturing site, taking total investment at the location to more than £50 million since 2022. The upgrade will add high‑speed, energy‑efficient production lines and increase warehousing capacity, allowing the company to...